Literature DB >> 30639047

Sex differences in vascular reactivity in mesenteric arteries from a mouse model of acute intermittent porphyria.

Victor M Pulgar1, Makiko Yasuda2, Lin Gan3, Robert J Desnick4, Herbert L Bonkovsky5.   

Abstract

BACKGROUND AND AIMS: Acute intermittent porphyria (AIP) results from a partial deficiency of porphobilinogen deaminase (PBGD). Symptomatic AIP patients, most of whom are women, experience acute attacks characterized by severe abdominal pain and abrupt increases in blood pressure. Here, we characterized the reactivity of mesenteric arteries from male and female AIP mice with ~30% of normal PBGD activity and wild type C57BL/6 mice.
METHODS: An acute porphyric attack was induced in AIP mice by treatment with phenobarbital. Vascular responses to K+, phenylephrine (PE), acetylcholine (ACh), and hemin were determined (Wire Multi Myograph).
RESULTS: Maximal contraction to PE was increased in arteries from male and female AIP mice (p < .05) during an induced attack of acute porphyria. Female AIP arteries had increased sensitivity to PE (p < .05) even after nitric oxide (NO) blockade with Nω-nitro-L-arginine methyl ester (L-NAME) (p < .05). Maximal relaxation to ACh was similar in males and females with lower sensitivity in female AIP arteries (p < .05). Hemin induced greater relaxation in AIP arteries in both males and females (p < .05). SUMMARY/
CONCLUSIONS: Sex differences in this AIP mouse model include a pro-contractile response in females. These alterations may contribute to the increased blood pressure during an acute attack and provide a novel mechanism of action whereby heme ameliorates the attacks.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5-Aminolevulinic acid; Acute intermittent porphyria (AIP); Heme; Hypertension; Porphobilinogen

Mesh:

Substances:

Year:  2019        PMID: 30639047      PMCID: PMC6612470          DOI: 10.1016/j.ymgme.2019.01.005

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  35 in total

Review 1.  Redox mechanisms of the beneficial effects of heme oxygenase in hypertension.

Authors:  Elsa C Chan; Gregory J Dusting; Guei-Sheung Liu; Fan Jiang
Journal:  J Hypertens       Date:  2014-07       Impact factor: 4.844

2.  Limited heme synthesis in porphobilinogen deaminase-deficient mice impairs transcriptional activation of specific cytochrome P450 genes by phenobarbital.

Authors:  R Jover; F Hoffmann; V Scheffler-Koch; R L Lindberg
Journal:  Eur J Biochem       Date:  2000-12

3.  Porphyria.

Authors:  D Montgomery Bissell; Karl E Anderson; Herbert L Bonkovsky
Journal:  N Engl J Med       Date:  2017-11-23       Impact factor: 91.245

4.  Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria.

Authors:  Eva Innala; Torbjörn Bäckström; Marie Bixo; Christer Andersson
Journal:  Acta Obstet Gynecol Scand       Date:  2010       Impact factor: 3.636

5.  Induction of placental heme oxygenase-1 is protective against TNFalpha-induced cytotoxicity and promotes vessel relaxation.

Authors:  A Ahmed; M Rahman; X Zhang; C H Acevedo; S Nijjar; I Rushton; B Bussolati; J St John
Journal:  Mol Med       Date:  2000-05       Impact factor: 6.354

6.  In hypertension, the kidney is not always the heart of the matter.

Authors:  Michael E Mendelsohn
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

Review 7.  Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye.

Authors:  J Flammer; M Pache; T Resink
Journal:  Prog Retin Eye Res       Date:  2001-05       Impact factor: 21.198

8.  Inhibition of Na+, K+-ATPase activity by delta-aminolevulinic acid.

Authors:  V A Russell; M C Lamm; J J Taljaard
Journal:  Neurochem Res       Date:  1983-11       Impact factor: 3.996

9.  Dominant role of smooth muscle L-type calcium channel Cav1.2 for blood pressure regulation.

Authors:  Sven Moosmang; Verena Schulla; Andrea Welling; Robert Feil; Susanne Feil; Jörg W Wegener; Franz Hofmann; Norbert Klugbauer
Journal:  EMBO J       Date:  2003-11-17       Impact factor: 11.598

10.  Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification.

Authors:  Amy Chan; Abigail Liebow; Makiko Yasuda; Lin Gan; Tim Racie; Martin Maier; Satya Kuchimanchi; Don Foster; Stuart Milstein; Klaus Charisse; Alfica Sehgal; Muthiah Manoharan; Rachel Meyers; Kevin Fitzgerald; Amy Simon; Robert J Desnick; William Querbes
Journal:  Mol Ther Nucleic Acids       Date:  2015-11-03       Impact factor: 10.183

View more
  1 in total

1.  Systematically Analyzing the Pathogenic Variations for Acute Intermittent Porphyria.

Authors:  Yibao Fu; Jinmeng Jia; Lishu Yue; Ruiying Yang; Yongli Guo; Xin Ni; Tieliu Shi
Journal:  Front Pharmacol       Date:  2019-09-13       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.